CureVac N.V. (CVAC)
| Previous close | 18.85 |
| Open | 18.85 |
| Bid | 19.56 x 1800 |
| Ask | 19.59 x 1000 |
| Day's range | 18.61 - 19.67 |
| 52-week range | 14.20 - 125.66 |
| Volume | |
| Avg. volume | 529,961 |
| Market cap | 3.644B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.37 |
| Earnings date | 15 Aug 2022 - 19 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.69 |
- Simply Wall St.
CureVac (NASDAQ:CVAC) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- EQS Group
CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
Issuer: CureVac / Key word(s): Quarter Results25.05.2022 / 13:05 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical tri
- EQS Group
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
Issuer: CureVac / Key word(s): Alliance25.05.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong
